Dossier assessment
Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V
Press releases
Romosozumab in osteoporosis: considerable added benefit for women after menopause
Fewer vertebral fractures and fewer other typical fractures in postmenopausal women with severe osteoporosis at high risk of fracture
Additional information
Federal Joint Committee (G-BA)
2020-09-03 A G-BA decision was published.
Project details
- Project no.
- A20-24
- Commission
- Commission awarded on 11.03.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.